Institut Bordet and Hôpital Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Maturitas. 2010 Jul;66(3):263-7. doi: 10.1016/j.maturitas.2010.03.016. Epub 2010 May 6.
The value of systematic mammographic screening has been studied in a total of 11 randomized trials - some of doubtful methodological quality - on various populations of women; the earliest dates from the 1960s. However, older women have been under-represented in these trials, as only six of them registered patients over 60 years of age. The proportion of women aged over 70 years was low and there are no data for patients older than 74. Several meta-analyses have been conducted and a plausible estimate of the impact of screening is a 16% reduction in breast cancer mortality (95% confidence interval 9-23%). Some meta-analyses provide "post hoc subgroup analyses" by age and these have found a greater benefit of screening for women of older age, with estimates of risk reductions of 17%, 27% and 22% for cohorts of women aged 55-64, 60-69 and 65-74; these figures are significantly different from 0. In comparison, for women in the age groups 40-49, 45-54 and 50-59 the estimated risk reductions were 9%, 7% and 12%. Nevertheless, there has been no formal demonstration of an interaction with age. When these estimates are translated into the number of women who need to be screened in order to avoid one death from breast cancer during 15 years of follow-up, the figure lies between 1370 and 4120. The probability of not dying from breast cancer within 15 years of screening for a 65-year-old woman is estimated to be in the range 98.85-99.11%, compared with 98.73% for a woman who does not undergo screening. These benefits should be balanced against the possible disadvantages of screening, including false positive results, overdiagnosis and overtreatment. One of the meta-analyses concluded that the rate of total mastectomies was significantly increased after screening. Although most scientific recommendations agree that screening should be proposed to all women aged 50-69 years, the benefits and disadvantages of mammography should be fully explained, in order to allow them to make a truly informed decision.
系统乳房 X 线筛查的价值已经在总共 11 项随机试验中进行了研究——其中一些试验的方法学质量存在疑问——这些试验涉及各种女性人群;最早的试验可以追溯到 20 世纪 60 年代。然而,这些试验中老年人的代表性不足,因为只有 6 项试验登记了 60 岁以上的患者。70 岁以上女性的比例较低,并且没有 74 岁以上患者的数据。已经进行了几项荟萃分析,筛查的影响的合理估计是乳腺癌死亡率降低 16%(95%置信区间为 9-23%)。一些荟萃分析提供了按年龄进行的“事后亚组分析”,这些分析发现,年龄较大的女性接受筛查的获益更大,55-64 岁、60-69 岁和 65-74 岁的女性队列的风险降低估计值分别为 17%、27%和 22%;这些数字与 0 显著不同。相比之下,40-49 岁、45-54 岁和 50-59 岁的女性的估计风险降低分别为 9%、7%和 12%。然而,没有正式证明与年龄之间存在交互作用。当这些估计值转化为为避免在 15 年随访期间死于乳腺癌,需要筛查的女性人数时,数字在 1370 到 4120 之间。对于 65 岁女性,在筛查后 15 年内死于乳腺癌的概率估计在 98.85-99.11%之间,而未接受筛查的女性则为 98.73%。这些益处应该与筛查的可能缺点相平衡,包括假阳性结果、过度诊断和过度治疗。一项荟萃分析的结论是,筛查后全乳房切除术的比率显著增加。尽管大多数科学建议都同意应向所有 50-69 岁的女性提出筛查建议,但应充分解释乳房 X 线摄影的益处和缺点,以便让她们做出真正知情的决定。